REFERENCES:

1. DeFelice, S. L. (1989). The Nutraceutical Revolution: Its Impact on Food Industry R&D. Foundation for Innovation in Medicine.
2. Kalra, E. K. (2003). Nutraceutical–definition and introduction. AAPS PharmSci, 5(3), E25.
3. Zeisel, S. H. (1999). Regulation of “nutraceuticals.” Science, 285(5435), 1853-1855.
4. Health Canada. (2007). Nutraceuticals/Functional Foods and Health Claims on Foods.
5. Patwardhan, B., et al. (2005). Ayurveda and natural products drug discovery. Current Science, 89(9), 1333–1342.
6. Shahidi, F. (2009). Nutraceuticals and functional foods: Whole versus processed foods. Trends in Food Science & Technology, 20(9), 376–387.
7. World Health Organization. (2020). Noncommunicable Diseases Fact Sheet.
8. Murray, C. J. L., & Lopez, A. D. (2013). Measuring the global burden of disease. New England Journal of Medicine, 369, 448–457.
9. Prince, M., et al. (2015). World Alzheimer Report: The Global Impact of Dementia. Alzheimer’s Disease International.
10. Kanis, J. A., et al. (2008). Epidemiology of osteoporosis. Osteoporosis International, 19(10), 1451–1458.
11. Ventola, C. L. (2010). The drug development process: a primer. Pharmacy and Therapeutics, 35(10), 615–636.
12. Gibson GR, Roberfroid MB. Dietary modulation of the human colonic microbiota: introducing the concept of prebiotics. J Nutr. 1995;125(6):1401–12.
13. Diplock AT, Aggett PJ, Ashwell M, Bornet F, Fern EB, Roberfroid MB. Scientific concepts of functional foods in Europe: consensus document. Br J Nutr. 1999;81(Suppl 1):S1–27.
14. Maughan RJ, Burke LM, Dvorak J, Larson-Meyer DE, Peeling P, Phillips SM, et al. IOC consensus statement: Dietary supplements and the high-performance athlete. Br J Sports Med. 2018;52(7):439–55.
15. Kalra EK. Nutraceutical—definition and introduction. AAPS PharmSci. 2003;5(3):E25.
16. U.S. Food and Drug Administration (FDA). Guidance for Industry: Frequently Asked Questions About Medical Foods. 2016. Available from: https://www.fda.gov/
17. Hill C, Guarner F, Reid G, Gibson GR, Merenstein DJ, Pot B, et al. The ISAPP consensus statement on the definition and scope of probiotics. Nat Rev Gastroenterol Hepatol. 2014;11(8):506–14.
18. Williamson EM. Synergy and other interactions in phytomedicines. Phytomedicine. 2001;8(5):401–9.
19. Simopoulos AP. Omega-3 fatty acids in inflammation and autoimmune diseases. J Am Coll Nutr. 2002;21(6):495–505.
20. Lobo V, Patil A, Phatak A, Chandra N. Free radicals, antioxidants and functional foods: Impact on human health. Pharmacogn Rev. 2010;4(8):118–26.
21. Pasiakos SM, McLellan TM, Lieberman HR. The effects of protein supplements on muscle mass, strength, and aerobic and anaerobic power in healthy adults: a systematic review. Sports Med. 2015;45(1):111–31.
22. Aggarwal BB, Sundaram C, Malani N, Ichikawa H. Curcumin: the Indian solid gold. Adv Exp Med Biol. 2007;595:1–75.
23. Chauhan B, Kumar G, Kalam N, Ansari SH. Current concepts and prospects of herbal nutraceutical: a review. J Adv Pharm Technol Res. 2013;4(1):4–8.
24. Tripathi YB, Pandey R. Role of nutraceuticals in health promotion. Ind J Nat Prod Resour. 2009;8(2):126–32.
25. Gupta RC, Chang D, Nammi S, Bensoussan A, Bilinski K, Roufogalis BD. Nutraceuticals in metabolic syndrome. Int J Mol Sci. 2010;11(2):520–28.
26. Kim SY, Park JY, Lee MY, et al. Effects of Zizyphus jujuba on memory impairment induced by scopolamine in mice. J Ethnopharmacol. 2000;70(1):49–56.
27. Bhupathiraju SN, Tucker KL. Coronary heart disease prevention: nutrients, foods, and dietary patterns. Clin Chim Acta. 2011;412(17–18):1493–514.
28. Baliga MS, Meera S, Mathai B, Rai MP, Pawar V, Palatty PL. Scientific validation of the ethnomedicinal properties of Ocimum sanctum L. (Holy Basil): a review. Int J Ayurveda Res. 2010;1(4):212–21.
29. Jeba Rani PJ, Shajahan A, Rajalakshmi M, Dhanasekaran M, Surendran S. Protective effect of Emblica officinalis (Indian gooseberry) on learning and memory in aging rats. J Clin Diagn Res. 2011;5(2):316–21.
30. Sharma U, Bala M, Kumar N, Singh B, Munshi RK, Bhalerao S. Immunomodulatory active compounds from Tinospora cordifolia. J Ethnopharmacol. 2012;141(3):918–26.
31. Saraf S, Ashawat MS, Saraf S. Flavonoids: a nutritional protection against oxidative and UV-induced skin damages. Pharma Times. 2007;39(5):19–23.
32. Peng WH, Hsieh MT, Lee YS, Lin YC, Liao J. Anxiolytic effect of seed of Ziziphus jujuba in mouse models of anxiety. Evid Based Complement Alternat Med. 2012;2012:451349.
33. Mahdy KAA, Hussien HM, Abdel-Razek HF. Antioxidant and neuroprotective activities of jujube (Ziziphus jujuba) in Alzheimer’s disease model. Int J Pharm Pharm Sci. 2016;8(10):189–95.
34. Rege NN, Thatte UM, Dahanukar SA. Adaptogenic properties of six rasayana herbs used in Ayurvedic medicine. Phytother Res. 1999;13(4):275–91.
35. Singh RH. Exploring issues in the development of Ayurvedic research methodology. J Ayurveda Integr Med. 2010;1(2):91–5.
36. Raut A, Rege NN, Tadvi FM, Solanki P, Kene KR, Shirolkar SG, et al. An exploratory study to evaluate the tolerability, safety, and activity of Ashwagandha (Withania somnifera) in healthy volunteers. J Ayurveda Integr Med. 2012;3(3):111–4.
37. Acharya SB, Frotan MH, Goel RK, Tripathi SK, Das PK. Pharmacological actions of Ocimum sanctum: the Indian holy basil. Ind J Exp Biol. 1996;34(12):1212–7.
38. Cicero AFG, Derosa G, Parini A, Maffioli P, Bove M, Borghi C. A randomized double-blind, placebo-controlled clinical study of the effects of a nutraceutical combination on LDL cholesterol levels and lipid pattern in subjects with suboptimal blood cholesterol levels. Nutrients. 2020;12(5):1405.
39. Kalepu S, Nekkanti V. Insoluble drug delivery strategies: review of recent advances and business prospects. Acta Pharm Sin B. 2015;5(5):442–53.
40. Dahan A, Miller JM. The solubility–permeability interplay and its implications in formulation design. Curr Opin Drug Discov Devel. 2010;13(1):116–23.
41. McClements DJ. Enhancing nutraceutical bioavailability through food matrix design. Curr Opin Food Sci. 2015;4:1 6.
42. Anand P, Kunnumakkara AB, Newman RA, Aggarwal BB. Bioavailability of curcumin: problems and promises. Mol Pharm. 2007;4(6):807–18.
43. Chen Y, Liu Y, Ding J, et al. Distribution of flavonoids in body tissues and their pharmacological effects. Curr Drug Metab. 2021;22(5):361–76.
44. Walle T. Bioavailability of resveratrol. Ann N Y Acad Sci. 2011;1215:9–15.
45. O’Hagan DT, Perrie Y. Pharmaceutical Excipients: Properties, Functionality and Applications in Research and Industry. London: Academic Press; 2012.
46. Mukerjee A, Vishwanatha JK. Formulation, characterization, and evaluation of curcumin-loaded PLGA nanospheres for cancer therapy. Anticancer Res. 2009;29(10):3867–75.
47. Maiti K, Mukherjee K, Gantait A, Saha BP, Mukherjee PK. Curcumin–phospholipid complex: preparation, therapeutic evaluation, and pharmacokinetic study in rats. Int J Pharm. 2007;330(1-2):155–63.
48. Shoba G, Joy D, Joseph T, Majeed M, Rajendran R, Srinivas PS. Influence of piperine on the pharmacokinetics of curcumin in animals and human volunteers. Planta Med. 1998;64(4):353–6.
49. Manach C, Williamson G, Morand C, Scalbert A, Rémésy C. Bioavailability and bioefficacy of polyphenols in humans. Am J Clin Nutr. 2005;81(1 Suppl):230S–42S.
50. Del Rio D, Rodriguez-Mateos A, Spencer JP, Tognolini M, Borges G, Crozier A. Dietary polyphenolics in human health: structures, bioavailability, and evidence of protective effects against chronic diseases. Antioxid Redox Signal. 2013;18(14):1818–92.
51. Gani OA, Sylte I. Insights into the molecular mechanisms of polyunsaturated fatty acids mediated activation of PPARs. J Mol Graph Model. 2008;27(2):217–29.
52. Kensler TW, Wakabayashi N, Biswal S. Cell survival responses to environmental stresses via the Keap1–Nrf2–ARE pathway. Annu Rev Pharmacol Toxicol. 2007;47:89 116.
53. Aggarwal BB, Harikumar KB. Potential therapeutic effects of curcumin, the anti-inflammatory agent, against neurodegenerative, cardiovascular, pulmonary, metabolic, autoimmune, and neoplastic diseases. Int J Biochem Cell Biol. 2009;41(1):40–59.
54. Chan GC, Chan WK, Sze DM. The effects of β-glucan on human immune and cancer cells. J Hematol Oncol. 2009;2:25.
55. Hardie DG. AMP-activated protein kinase: an energy sensor that regulates all aspects of cell function. Genes Dev. 2011;25(18):1895–908.
56. Surh YJ. Cancer chemoprevention with dietary phytochemicals. Nat Rev Cancer. 2003;3(10):768–80.
57. Kennedy DO, Scholey AB, Wesnes KA. Dose-dependent changes in cognitive performance and mood following acute administration of Ginkgo biloba to healthy young volunteers. Nutr Neurosci. 2000;3(6):413–21.
58. Setchell KD, Cassidy A. Dietary isoflavones: biological effects and relevance to human health. J Nutr. 1999;129(3):758S–67S.
59. Williamson EM. Synergy and other interactions in phytomedicines. Phytomedicine. 2001;8(5):401–9.
60. U.S. Food and Drug Administration. Dietary Supplement Health and Education Act of 1994. [Internet]. Available from: https://www.fda.gov
61. U.S. Food and Drug Administration. Label Claims for Conventional Foods and Dietary Supplements. [Internet]. Available from: https://www.fda.gov/food/food-labeling-nutrition
62. European Commission. Regulation (EC) No. 178/2002 of the European Parliament and of the Council. Official Journal of the European Communities.
63. EFSA Panel on Dietetic Products, Nutrition and Allergies (NDA). Scientific and technical guidance for the preparation and presentation of the application for authorization of health claims. EFSA Journal. 2016;14(1):4367.
64. Food Safety and Standards Authority of India. Food Safety and Standards (Health Supplements, Nutraceuticals, Food for Special Dietary Use, Food for Special Medical Purpose and Functional Foods) Regulations, 2016. [Internet]. Available from: https://www.fssai.gov.in
65. Ministry of AYUSH, Government of India. Guidelines for Evaluation of Ayurvedic Products. [Internet]. Available from: https://www.ayush.gov.in
66. Ministry of Health, Labour and Welfare (Japan). Foods for Specified Health Uses (FOSHU). [Internet]. Available from: https://www.mhlw.go.jp/english/
67. Gurley BJ, Fifer EK, Gardner SF. Pharmacokinetic herb-drug interactions (Part 1): Origins, mechanisms, and the impact of botanical dietary supplements. Planta Med. 2000;66(5):396–405.
68. Izzo AA, Ernst E. Interactions between herbal medicines and prescribed drugs: A systematic review. Drugs. 2001;61(15):2163–75.
69. Zhou S, Chan E, Pan S, Huang M, Lee EJ. Pharmacokinetic interactions of drugs with St. John’s Wort. J Psychopharmacol. 2004;18(2):262–76.
70. Saper RB, Eisenberg DM, Phillips RS. Heavy metal content of ayurvedic herbal medicine products. JAMA. 2004;292(23):2868–73.
71. Koh HL, Woo SO. Chinese proprietary medicine in Singapore: Regulatory control of toxic heavy metals and undeclared drugs. Drug Saf. 2000;23(5):351–62.
72. Geller AI, Shehab N, Weidle NJ, Lovegrove MC, Wolpert BJ, Timbo BB, et al. Emergency department visits for adverse events related to dietary supplements. N Engl J Med. 2015;373(16):1531–40.
73. Rani N, Bharti S, Krishnamurthy B, Arya DS. Pharmacological properties of nutraceuticals: Mechanistic insights. Curr Pharm Des. 2016;22(1):1–13.
74. Halliwell B. Free radicals and antioxidants: Updating a personal view. Nutr Rev. 2012;70(5):257–65.
75. Aggarwal BB, Harikumar KB. Potential therapeutic effects of curcumin, the anti-inflammatory agent, against neurodegenerative, cardiovascular, pulmonary, metabolic, autoimmune, and neoplastic diseases. Int J Biochem Cell Biol. 2009;41(1):40–59.
76. Venkatesh S, Weidner M, Kiefer D. Immunomodulatory herbs: Evidence-based applications in integrative medicine. Altern Ther Health Med. 2020;26(1):12–21.
77. Liu Z, Patil IY, Jiang T, Sancheti H, Walsh JP, Stiles BL, et al. Nutraceutical intervention in metabolic disorders: Mechanistic roles and clinical applications. Trends Mol Med. 2013;19(10):593–605.
78. Loguercio C, Federico A. Oxidative stress in viral and alcoholic hepatitis. Free Radic Biol Med. 2003;34(1)::1–10.
79. Cicero AFG, Colletti A, Bajraktari G, Descamps OS, Djuric DM, Ezhov M, et al. Lipid-lowering nutraceuticals in clinical practice: Position paper from an International Lipid Expert Panel. Arch Med Sci. 2017;13(5):965–1005.
80. Joseph JA, Shukitt-Hale B, Casadesus G. Reversing the deleterious effects of aging on neuronal communication and behavior: Beneficial properties of fruit polyphenolic compounds. Am J Clin Nutr. 2005;81(1):313S–316S.
81. Roberfroid MB. Global view on functional foods: European perspectives. Br J Nutr. 2002;88(S2):S133–S138.
82. Libby P. Inflammation in atherosclerosis. Nature. 2002;420(6917):868–74.
83. Rahman K, Lowe GM. Garlic and cardiovascular disease: a critical review. J Nutr. 2006;136(3):736S–740S.
84. Calder PC. Omega-3 polyunsaturated fatty acids and inflammatory processes. Nutrients. 2010;2(3):355–74.
85. Gao L, Mao Q, Cao J, Wang Y, Zhou X, Fan L. Coenzyme Q10 treatment of cardiovascular disorders: An overview of current research. J Cardiovasc Pharmacol. 2010;56(3):208–14.
86. Hollman PCH, Katan MB. Dietary flavonoids: Intake, health effects, and bioavailability. Food Chem Toxicol. 1999;37(9–10):937–42.
87. DeFronzo RA. Pathogenesis of type 2 diabetes mellitus. Med Clin North Am. 2004;88(4):787–835.
88. Nerurkar PV, Lee YK, Nerurkar VR. Momordica charantia (bitter melon) inhibits primary human adipocyte differentiation by modulating adipogenic genes. BMC Complement Altern Med. 2010;10:34.
89. Basch E, Ulbricht C, Kuo G, Szapary P, Smith M. Therapeutic applications of fenugreek. Altern Med Rev. 2003;8(1):20–7.
90. Qin B, Polansky MM, Sato Y, Anderson RA. Cinnamon extract inhibits glucose uptake and insulin signaling pathways. Horm Res. 2010;73(1):30–7.
91. Weisberg SP, Leibel R, Tortoriello DV. Dietary curcumin significantly improves obesity-associated inflammation and diabetes in mouse models. Endocrinology. 2008;149(7):3549–58.
92. Mattson MP. Pathways towards and away from Alzheimer’s disease. Nature. 2004;430(7000):631–9.
93. Diamond BJ, Shiflett SC, Feiwel N, Matheis RJ, Noskin O, Richards JA, et al. Ginkgo biloba extract: Mechanisms and clinical indications. Arch Phys Med Rehabil. 2000;81(5):668–78.
94. Yang F, Lim GP, Begum AN, Ubeda OJ, Simmons MR, Ambegaokar SS, et al. Curcumin inhibits the formation of amyloid beta oligomers and fibrils, binds plaques, and reduces amyloid in vivo. J Biol Chem. 2005;280(7):5892–901.
95. Baur JA, Sinclair DA. Therapeutic potential of resveratrol: The in vivo evidence. Nat Rev Drug Discov. 2006;5(6):493–506.
96. Dyall SC. Long-chain omega-3 fatty acids and the brain: A review of the independent and shared effects of EPA, DPA, and DHA. Front Aging Neurosci. 2015;7:52.
97. Rose NR. Negative selection, epitope mimicry, and autoimmunity. Curr Opin Immunol. 2017;49:51 5.
98. Chandrasekhar K, Kapoor J, Anishetty S. A prospective, randomized double-blind, placebo-controlled study of safety and efficacy of a high-concentration full-spectrum Ashwagandha extract. Indian J Psychol Med. 2012;34(3):255–62.
99. Mondal S, Varma S, Bamola VD, Naik SN, Mirdha BR, Padhi MM, et al. Double-blinded randomized controlled trial for immunomodulatory effects of Tulsi (Ocimum sanctum Linn.) leaf extract on healthy volunteers. J Ethnopharmacol. 2011;136(3):452–6.
100. Vetvicka V, Oliveira C, Pontes P, Rivera I. β-glucans as immunomodulators: Clinical trials and possible future applications. Int J Mol Sci. 2019;20(6):1255.
101. Younossi ZM. Non-alcoholic fatty liver disease – A global public health perspective. J Hepatol. 2019;70(3):531–44.
102. Pradhan SC, Girish C. Hepatoprotective herbal drug, silymarin from experimental pharmacology to clinical medicine. Indian J Med Res. 2006;124(5):491–504.
103. Al-Fartosi KG, Majid SA, Ahmed DS. Antioxidant activity of papaya fruit extracts against hydrogen peroxide-induced oxidative stress in liver cells. J Med Plants Res. 2010;4(12):1125–30.
104. Boudreau MD, Beland FA. An evaluation of the biological and toxicological properties of Aloe vera. Environ Health Perspect. 2006;114(3):349–55.
105. Zouboulis CC, Makrantonaki E. Clinical aspects and molecular diagnostics of skin aging. Clin Dermatol. 2011;29(1):3–14.
106. Surjushe A, Vasani R, Saple DG. Aloe vera: A short review. Indian J Dermatol. 2008;53(4):163–6.
107. Heng MC. Curcumin and turmeric in dermatology: Molecular targets and clinical relevance. Phytother Res. 2010;24(5):651–6.
108. Nichols JA, Katiyar SK. Skin photoprotection by natural polyphenols: Anti-inflammatory, antioxidant and DNA repair mechanisms. Arch Dermatol Res. 2010;302(2):71–83.
109. Calder PC. Nutrition, immunity, and COVID-19. BMJ Nutr Prev Health. 2020;3(1):74–92.
110. Ministry of AYUSH. Ayush Kadha Guidelines. Government of India. [Internet]. Available from: https://www.ayush.gov.in
111. Carr AC, Maggini S. Vitamin C and immune function. Nutrients. 2017;9(11):1211.
112. Sharma U, Bala M, Kumar N, Singh B, Munshi RK, Bhalerao S. Immunomodulatory active compounds from Tinospora cordifolia. J Ethnopharmacol. 2012;141(3):918–26.
113. Martirosyan DM, Singh J. A new definition of functional food by FFC: What makes a new definition unique? Functional Foods in Health and Disease. 2015;5(6):209–23.
114. Kussmann M, Van Bladeren PJ. The extended nutrigenomics—understanding dietary health effects at the systems level. Genome Med. 2011;3(7):44.
115. Ferguson LR. Nutrigenomics approaches to functional foods. J Am Diet Assoc. 2009;109(3):452–8.
116. Zeisel SH, Da Costa KA. Nutrigenomics and metabolomics will change clinical nutrition and public health practice: Insights from studies on dietary requirements for choline. Am J Clin Nutr. 2009;89(2):539–44.
117. Rehman MU, Rizvi MM, Khan R, Khan AQ, Sheikh RA, Feroze N, et al. Emerging technologies in nutraceutical delivery: A comprehensive review. Crit Rev Food Sci Nutr. 2022;62(1):27–56.
118. Maki KC, Reeves MS, Farmer M, Griinari M, Berge K, Vik H, et al. Krill oil supplementation increases plasma concentrations of eicosapentaenoic and docosahexaenoic acids in overweight and obese men and women. Nutr Res. 2009;29(9):609–15.
119. Hamilton AC. Medicinal plants, conservation, and livelihoods. Biodivers Conserv. 2004;13(8):1477–517.